Preventing Moderate to Severe Dermatologic Adverse Events in First-Line EGFR-Mutant Advanced NSCLC Treated With Amivantamab Plus Lazertinib: Early Success of the COCOON Trial
Alexander Spira, MD, PhD, FACP, FASCO, and Randi Rabin, MPH, MSc, PA-C, discuss how proactive dermatologic adverse event management—specifically through the COCOON protocol—enhances treatment adherence, reduces toxicity, and improves quality of life for patients with EGFR-mutant non–small cell lung cancer receiving amivantamab plus lazertinib.
EP. 1: Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
April 23rd 2025Panelists discuss how amivantamab plus lazertinib therapy for EGFR-mutant non–small cell lung cancer has shown promising survival data while highlighting the importance of managing adverse events for improved quality of life.
EP. 2: Overview of Study Design of the COCOON Trial
April 23rd 2025Panelists discuss how the COCOON trial demonstrated that enhanced dermatologic management significantly reduced grade 2 or higher skin-related adverse events (38% vs 76%) compared with standard of care for patients receiving amivantamab plus lazertinib.
